Paul J. Kostenuik

RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism

Ji Li, Ildiko Sarosi, Xiaoqiang Yan et al. · Proceedings of the National Academy of Sciences · 2000 · 1.1K citations

Medicine, Cell Biology, Genetics +17

Targeted Deletion of the Sclerostin Gene in Mice Results in Increased Bone Formation and Bone Strength

Xiaodong Li, Michael S. Ominsky, Qing‐Tian Niu et al. · Journal of Bone and Mineral Research · 2008 · 938 citations · Full text

Medicine, Genetics, Molecular Genetics +17

Sclerostin Antibody Treatment Increases Bone Formation, Bone Mass, and Bone Strength in a Rat Model of Postmenopausal Osteoporosis

Xiaodong Li, Michael S. Ominsky, Kelly Warmington et al. · Journal of Bone and Mineral Research · 2008 · 784 citations

Medicine, Biochemistry, Endocrinology +16

Osteoprotegerin Reverses Osteoporosis by Inhibiting Endosteal Osteoclasts and Prevents Vascular Calcification by Blocking a Process Resembling Osteoclastogenesis

Hosung Min, Sean Morony, Ildiko Sarosi et al. · The Journal of Experimental Medicine · 2000 · 559 citations · Full text

Medicine, Oral Biology, Bone Metabolism +13

Denosumab, a Fully Human Monoclonal Antibody to RANKL, Inhibits Bone Resorption and Increases BMD in Knock-In Mice That Express Chimeric (Murine/Human) RANKL

Paul J. Kostenuik, Hung Q. Nguyen, James McCabe et al. · Journal of Bone and Mineral Research · 2008 · 436 citations

Medicine, Immunology, Molecular Medicine +17